

Table 1. Patient characteristics, treatment history and concomitant medication at baseline.

	CD	UC
IBD diagnosis, n (%)	104 (38.0)	170 (62.0)
Gender (female/male), n (%)	37 / 67 (35.6 / 64.4)	59 / 111 (34.7 / 65.3)
Age, years, median (range)	37.5 (18-70)	37 (20-69)
Disease duration, years, median (range)	12 (1-53)	37 (1-42)
BMI, median (range)	26.5 (17.2-42.9)	26.3 (16.9-53.2)
Smoking, n (%)		
- current	17 (16.3)	15 (8.8)
- previous	22 (21.1)	27 (15.9)
- never	61 (58.7)	115 (67.6)
Montreal classification, n (%)		
- A1 (age at diagnosis, < 17 years)	27 (26.0)	
- A2 (17-40 years)	67 (64.4)	
- A3 (>40 years)	10 (9.6)	
- L1 (disease extent, ileal)	13 (12.6)	
- L2 (colonic)	21 (20.4)	
- L3 (ileocolonic)	43 (41.8)	
- L1/L2/L3 + L4 (+ upper GI)	26 (25.0)	
- B1 (behaviour, non-stricturing and non-penetrating)	61 (58.6)	
- B2 (stricturing)	22 (21.2)	
- B3 (penetrating)	21 (20.2)	
- p (perianal disease)	28 (26.9)	
- E1 (proctitis)		4 (2.4)
- E2 (left-sided colitis)		55 (32.4)
- E3 (extensive colitis)		111(65.3)
Extraintestinal manifestations*, n (%)	12 (11.5)	14 (8.2)
Previous biological therapy, n (%)		
- adalimumab or ustekinumab	15 (14.4)	4 (2.4)
- previous treatment course of IFX, n (%)	13 (12.5)	16 (9.4)
Previous surgical therapy, n (%)	34 (32.7)	0
Clinical remission based on HBI or PMS, n (%)	98 (94.2)	153 (90.0)
Influence of symptoms on daily life (IBD-VAS), median (range)	1 (0-6)	1 (0-7)
Faecal calprotectin, µg/g, median (range)	36 (3-1404)	34 (3-1944)
Concomitant medication, n (%)		
- 5-ASA	10 (9.6)	65 (38.2)
- immunomodulator	67 (64.4)	117 (68.8)
- corticosteroid	3 (2.9)	3 (1.8)

*Extraintestinal manifestations included arthropathy, erythema nodosum, pyoderma gangrenosum, ophthalmic manifestations and primary sclerosing cholangitis.